Immuron (ASX:IMC) Effective Interest Rate on Debt %: 19.44% (As of Dec. 2025)


What is Immuron Effective Interest Rate on Debt %?

Immuron ASX:IMC +8.33% Effective Interest Rate on Debt % is 19.44% as of Dec. 2025. The stock has 4 warning signs investors should review.

Effective Interest Rate on Debt % is the usage rate that a borrower actually pays on a debt. It is calculated as the positive value of Interest Expense divided by its average total debt. Total debt equals to Long-Term Debt & Capital Lease Obligation plus Short-Term Debt & Capital Lease Obligation. Immuron's annualized positive value of Interest Expense for the quarter that ended in Dec. 2025 was A$0.01 Mil. Immuron's average total debt for the quarter that ended in Dec. 2025 was A$0.07 Mil. Therefore, Immuron's annualized Effective Interest Rate on Debt % for the quarter that ended in Dec. 2025 was 19.44%.

Immuron  (ASX:IMC) Effective Interest Rate on Debt % Explanation

Effective Interest Rate on Debt % measures the usage rate that a borrower actually pays on a debt.

Immuron Effective Interest Rate on Debt % Related Terms

Immuron Effective Interest Rate on Debt % Historical Data

* Premium members only.

The historical data trend for Immuron's Effective Interest Rate on Debt % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Immuron Effective Interest Rate on Debt % Chart

Immuron Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Effective Interest Rate on Debt %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 73.68 2.87 5.03 4.97 6.83

Immuron Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Effective Interest Rate on Debt % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.23 6.02 6.02 8.33 19.44

ASX:IMC vs VRTX, REGN, ALNY: Effective Interest Rate on Debt % Comparison

For the Biotechnology subindustry, Immuron's Effective Interest Rate on Debt %, along with its competitors' market caps and Effective Interest Rate on Debt % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Immuron Effective Interest Rate on Debt % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Immuron's Effective Interest Rate on Debt % distribution charts can be found below:

* The bar in red indicates where Immuron's Effective Interest Rate on Debt % falls into.


Immuron Effective Interest Rate on Debt % Calculation

Immuron's annualized Effective Interest Rate on Debt % for the fiscal year that ended in Jun. 2025 is calculated as

Effective Interest Rate on Debt %
=-1  *  Interest Expense/( (Total Debt  (A: Jun. 2024 )+Total Debt  (A: Jun. 2025 ))/ count )
=-1  *  -0.007/( (0.133+0.072)/ 2 )
=-1  *  -0.007/0.1025
=6.83 %

where

Total Debt  (A: Jun. 2024 )
=Long-Term Debt & Capital Lease Obligation + Short-Term Debt & Capital Lease Obligation
=0.133 + 0
=0.133

Total Debt  (A: Jun. 2025 )
=Long-Term Debt & Capital Lease Obligation + Short-Term Debt & Capital Lease Obligation
=0.072 + 0
=0.072

Immuron's annualized Effective Interest Rate on Debt % for the quarter that ended in Dec. 2025 is calculated as

Effective Interest Rate on Debt %
=-1  *  Interest Expense/( (Total Debt  (Q: Jun. 2025 )+Total Debt  (Q: Dec. 2025 ))/ count )
=-1  *  -0.014/( (0.072+0)/ 1 )
=-1  *  -0.014/0.072
=19.44 %

where

Total Debt  (Q: Jun. 2025 )
=Long-Term Debt & Capital Lease Obligation + Short-Term Debt & Capital Lease Obligation
=0.072 + 0
=0.072

Total Debt  (Q: Dec. 2025 )
=Long-Term Debt & Capital Lease Obligation + Short-Term Debt & Capital Lease Obligation
=0 + 0
=0

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Effective Interest Rate on Debt %, the Interest Expense of the last fiscal year and the average total debt over the fiscal year are used. In calculating the quarterly data, the Interest Expense data used here is two times the semi-annual (Dec. 2025) interest expense data. Effective Interest Rate on Debt % is displayed in the 30-year financial page.

What does a Effective Interest Rate on Debt % of 19.44% mean?
Immuron (ASX:IMC) has a Effective Interest Rate on Debt % of 19.44% as of Dec. 2025. Effective interest rate on debt is the rate a company actually pays on its debt. View historical data on Immuron and its competitors.
Is Immuron's Effective Interest Rate on Debt % too high?
Immuron's current Effective Interest Rate on Debt % is 19.44%.
How does Immuron's Effective Interest Rate on Debt % compare to VRTX and REGN?
Immuron's Effective Interest Rate on Debt % of 19.44% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Effective Interest Rate on Debt % for a Biotechnology company?
A good Effective Interest Rate on Debt % depends on the Biotechnology industry context. However, Effective Interest Rate on Debt % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Effective Interest Rate on Debt % mean?
A high Effective Interest Rate on Debt % can signal that a stock is expensive relative to its fundamentals. Effective interest rate on debt is the rate a company actually pays on its debt. View historical data on Immuron and its competitors. Immuron's current Effective Interest Rate on Debt % is 19.44%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Immuron stock overvalued right now?
Based on GuruFocus' analysis, Immuron (ASX:IMC) is currently considered Possible Value Trap. The stock's GF Value™ is A$0.23, compared to a current price of A$0.04 — trading 83% below its estimated fair value. The current Effective Interest Rate on Debt % is 19.44%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Effective Interest Rate on Debt % calculated?
Effective Interest Rate on Debt % is calculated from a company's financial statements. For Immuron (ASX:IMC), the current Effective Interest Rate on Debt % is 19.44% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Immuron Business Description

Other Exchanges IMRN:USAANW:Germany
Address 25-37, Chapman Street, Unit 10, Blackburn, Melbourne, VIC, AUS, 3130
Immuron Ltd is a commercial and clinical-stage biopharmaceutical company with a proprietary technology platform focused on polyclonal antibodies that can address unmet medical needs. The company's commercial products are: Travelan (an orally administered passive product indicated to reduce the risk of travelers' diarrhea and minor gastrointestinal disorders), and Protectyn, which is marketed as an immune supplement. Additionally, it has two clinical products in development, IMM124-E and IMM529, for the treatment of multiple high-value enteric disease indications. The firm has two reportable segments: Hyper-immune products, which derive maximum revenue, and Research and development. Geographically, the company generates maximum revenue from Australia, followed by the USA and Canada.